Annual Securities Report — FY2025
What CanBas Co.,Ltd. reported for the period from 2025-07-01 to 2026-06-30.
Filed 2026-09-29View the original on EDINET
How much it says
37Thin
What moved here
7named for the first time
Its own wording
45terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
Following the successful completion of the Phase 2 clinical trial for CBP501, the company proceeded with preparations for the next clinical trial phase while continuing basic research and exploration and development preparations for subsequent pipelines, including CBT005, CBP-A08 and IDO/TDO inhibitors. Financially, the company recorded no product sales during the fiscal year, posted an operating loss and a net loss for the period due to research and development expenses and other costs, and saw its cash and cash equivalents decrease.
Komori's summary of this document, not the document's own words.37Thin
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
81
Very detailed
38
Thin
0
Almost nothing
50
Typical
0
Almost nothing
55
Typical
31
Thin
7
Almost nothing
55
Typical
50
Typical
R&D spend11億円Money spent making new things.
Cash left over-14億円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
Employees18Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.